MCKESSON CORPMCK
MCKESSON CORP Financial Overview 2022–2026
Updated Jul 10, 2026McKesson Corporation drove a massive profitability surge by pivoting away from international retail to focus on domestic specialty care, sending diluted earnings per share to $38.38 in FY2026. This strategic narrowing highlights a clear investment thesis: shedding peripheral global operations to dominate U.S. oncology and prescription technology unlocks tremendous shareholder value. Total revenue grew from $264 billion in FY2022 to $403.4 billion in FY2026, capped by a 12% year-over-year expansion fueled heavily by higher drug utilization in the U.S. Pharmaceutical segment.
To execute this shift, the distributor aggressively restructured its portfolio. McKesson absorbed fair-value charges to exit Europe and Canada—including a $667 million hit in FY2025 for its Canadian retail divestiture—while reallocating capital into high-growth targets. During FY2026, the company deployed $3.37 billion to acquire PRISM Vision and Core Ventures. It also struck a $1.25 billion deal to sell a minority stake in its Medical-Surgical unit to Apollo Funds. Despite managing an ongoing opioid litigation liability that stood at $5.7 billion at the end of FY2026, cash generation remained strong enough to return $5.1 billion to shareholders through buybacks and dividends that year.
The market has rewarded this operational focus and share reduction. At the close of FY2025, the stock traded at 26.2x earnings with a price of $672.99. As the benefits of the oncology acquisitions and sustained revenue growth materialized, the equity climbed to $865.36 by the end of FY2026.
Recent Developments (Q3 and Q4 2026)
In Q3 2026, total revenue rose 11% year-over-year to $106.2 billion, lifting quarterly diluted earnings per share by 38% to $9.59. During the first nine months, gross profit climbed 8% while total operating expenses declined 6%, highlighting aggressive cost control. To optimize its capital structure, the company secured a new $5.0 billion revolving credit facility in April 2026, capped by a 4.25x debt-to-EBITDA covenant, followed by a $2.25 billion term loan in June 2026.
Significant leadership turnover is also approaching. Kenny K. Cheung assumes the Chief Financial Officer role on May 29, 2026, and Chief Strategy Officer Thomas L. Rodgers retires on August 1, 2026. Bulls see tremendous operating leverage as falling expenses amplify double-digit top-line growth. Conversely, bears worry that simultaneous C-suite transitions and new debt loads create execution risks, especially with the stock trading at 28.6x earnings as of May 8, 2026.
What to watch: leverage ratio fluctuations following recent credit facility expansions; strategic continuity under the incoming executive team.
Rev
$359.05B
FY2025
NI
$3.29B
FY2025
EPS
$25.86
FY2025
OCF
$6.08B
FY2025
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
Recent SEC Filings
MCKESSON CORP 8-K Report, Executive Changes (Jul 1, 2026)
McKesson Corporation (MCK) has announced a significant executive transition, with Thomas L. Rodgers, Executive Vice President, Chief Strategy and Business Development Officer, intending to retire effective August 1, 2026. Mr. Rodgers has served as a key named executive officer, and his departure marks the end of his tenure with the company. The company has also taken proactive steps to ensure a smooth handover by appointing Ramesh Srinivasan to the newly titled position of Executive Vice President, Chief Strategy Officer, also effective August 1, 2026. This strategic appointment underscores McKesson's commitment to maintaining continuity and leadership in its strategic initiatives during this period of change.
MCKESSON CORP 8-K Report, Material Agreement (Jun 12, 2026)
McKesson Corporation (MCK) announced on June 12, 2026, through an 8-K filing, the entry into a material definitive agreement related to its credit facilities. Specifically, certain subsidiaries, including McKesson Medical-Surgical Top Holdings, Inc. (the Borrower), have amended their existing Credit Agreement. This amendment establishes a new $2,250.0 million senior secured term "B" loan facility due in 2032. This new financing provides the Company with substantial liquidity and extends its debt maturity profile. The Term B Loan Facility bears interest at a variable rate, offering the Borrower the option between Adjusted Term SOFR Rate plus a 2.25% margin or a Base Rate plus a 1.25% margin, with the Borrower initially electing the SOFR-based rate. The obligations are secured by substantially all tangible and intangible assets of the Borrower and certain material U.S. subsidiaries, and the facility includes financial covenants related to total net leverage and interest coverage ratios.
MCKESSON CORP 8-K Report, Financial Results (May 7, 2026)
McKesson Corporation (MCK) filed an 8-K on May 7, 2026, to report preliminary financial results for the fiscal quarter and full fiscal year ended March 31, 2026. While specific financial figures are not detailed within the 8-K itself, it directs investors to an attached earnings release (Exhibit 99.1) for comprehensive details. This filing serves as a notification of the release of this important financial data, allowing investors to access the performance metrics for the recently concluded fiscal period. Investors should refer to the earnings release (Exhibit 99.1) for key financial data, including revenue, earnings per share, and any guidance provided for the upcoming fiscal year. This information is crucial for understanding McKesson's operational performance, profitability, and future outlook. The filing clarifies that this information is furnished and not deemed "filed" for certain regulatory purposes, a standard disclosure for this type of announcement.
MCKESSON CORP 8-K Report, Material Agreement (Apr 28, 2026)
McKesson Corporation (MCK) announced on April 28, 2026, the execution of a new, larger revolving credit facility. This new facility, totaling $5.0 billion, replaces two previous credit agreements with a combined capacity of $5.0 billion. The new agreement extends the maturity date to April 2031, providing enhanced long-term financial flexibility. Crucially, the new credit facility introduces a financial covenant requiring McKesson to maintain a total debt to Consolidated EBITDA ratio of no greater than 4.25x, with a temporary step-up to 4.75x allowed following significant acquisitions. This covenant is important for investors as it sets a clear leverage limit, though it excludes the Medical-Surgical Solutions segment. The company had no outstanding borrowings under its previous facilities at the time of this transition, indicating a proactive approach to its capital structure.
MCKESSON CORP 8-K Report, Material Agreement (Apr 6, 2026)
McKesson Corporation (MCK) announced a significant financing event through an 8-K filing on April 6, 2026. The Company's subsidiary, McKesson Medical-Surgical Top Holdings, Inc., entered into a new Senior Secured Credit Facilities agreement on April 1, 2026. This agreement provides substantial liquidity, comprising a $750.0 million Term Loan A-1 facility due in 2031 and a $250.0 million Term Loan A-2 facility due in 2028, totaling $1.0 billion in term loans. Additionally, a $1.0 billion senior secured revolving credit facility, maturing in April 2031, offers further financial flexibility. This new credit facility, secured by substantially all assets of the borrower and certain subsidiaries, will be used by the Company to manage its ongoing operational and strategic needs.
View all 8-K filings →